PreludeDx

PreludeDx™, provider of DCISionRT®, is a prognostic and predictive test for risk of recurrence and radiation therapy benefit for women diagnosed with DCIS. The information provided helps with individualized decision-making. The predictive Radio-Genomic DCISionRT® reliably reclassifies risk better than the traditional method of Clinical Pathology. Utilizing non-linear modeling, DCISionRT® upstages 53% more patients than Clinical Pathology to 10-year Elevated Risk of recurrence and downgrades a third more patients into Low Risk. To learn more about DCISionRT®, the only individualized risk assessment assay guidance tool that provides the benefit of radiation therapy for DCIS patients, go to https://preludedx.com/.